Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

  1. Irigoyen, A.
  2. Gallego, J.
  3. Guillén Ponce, C.
  4. Vera, R.
  5. Iranzo, V.
  6. Ales, I.
  7. Arévalo, S.
  8. Pisa, A.
  9. Martín, M.
  10. Salud, A.
  11. Falcó, E.
  12. Sáenz, A.
  13. Manzano Mozo, J.L.
  14. Pulido, G.
  15. Martínez Galán, J.
  16. Pazo-Cid, R.
  17. Rivera, F.
  18. García García, T.
  19. Serra, O.
  20. Fernández Parra, E.M.
  21. Hurtado, A.
  22. Gómez Reina, M.J.
  23. López Gomez, L.J.
  24. Martínez Ortega, E.
  25. Benavides, M.
  26. Aranda, E.
  27. Show all authors +
Journal:
European Journal of Cancer

ISSN: 1879-0852 0959-8049

Year of publication: 2017

Volume: 75

Pages: 73-82

Type: Article

DOI: 10.1016/J.EJCA.2016.12.032 GOOGLE SCHOLAR